Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Does New IV Urticaria Medication Offer Benefits Over Current Treatments?

By Ryan Patrick Radecki, MD, MS | on June 15, 2021 | 2 Comments
Features Pearls From the Medical Literature
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version
shutterstock.com

References

  1. Abella BS, Berger WE, Blaiss MS, et al. Intravenous cetirizine versus intravenous diphenhydramine for the treatment of acute urticaria: a phase III randomized controlled noninferiority trial. Ann Emerg Med. 2020;76(4):489-500.
  2. NDA multidisciplinary review and evaluation {NDA 211415} {Quzyttir (cetirizine hydrochloride injection) for intravenous use}. U.S. Food and Drug Administration website. Accessed May 18, 2021.
  3. Schaefer P. Acute and chronic urticaria: evaluation and treatment. Am Fam Physician. 2017;95(11):717-724.
  4. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145(4):1082-1123.
  5. Zyrtec (cetirizine hydrochrloride) tablets and syrup for oral use. U.S. Food and Drug Administration website. Accessed May 18, 2021.
  6. Drug monograph: Quzyttir. Conduent website. Accessed May 18, 2021.

You Might Also Like
  • Current Workplace Laws Offer Protections but Aren’t Optimized for EM
  • Two Generic Drugs Being Tested in U.S. in Race to Find Coronavirus Treatments
  • Corticosteroid Treatments for Asthma Exacerbation, Intussusception Recurrence in Pediatric Patients
Explore This Issue
ACEP Now: Vol 40 – No 06 – June 2021

Pages: 1 2 3 | Single Page

Topics: AllergycetirizinehivesQuzyttirRashurticaria

Related

  • Visual Dx Answer: a) Measles

    June 4, 2025 - 0 Comment
  • Visual Dx Question: What Is This Rash?

    June 4, 2025 - 0 Comment
  • A Rash Plus Abdominal Pain May Equal Henoch-Schönlein Purpura

    April 17, 2019 - 0 Comment

Current Issue

ACEP Now: June 2025 (Digital)

Read More

About the Author

Ryan Patrick Radecki, MD, MS

Ryan Patrick Radecki, MD, MS, is an emergency physician and informatician with Christchurch Hospital in Christchurch, New Zealand. He is the Annals of Emergency Medicine podcast co-host and Journal Club editor and can be found on Twitter @emlitofnote.

View this author's posts »

2 Responses to “Does New IV Urticaria Medication Offer Benefits Over Current Treatments?”

  1. July 19, 2021

    Dr. Joseph Sachter Reply

    Excellent review — as usual. Although I might use the intravenous preparation a little more frequently than “almost never’ (an unaccompanied patient who drove to themselves to the ED and might otherwise be ready for discharge a couple of hours after treatment initiation), the $300 a dose price is a dealbreaker.

    This in turn brings up an interesting economic question. Wouldn’t TerSera (marketers of the drug) make more money overall if they charged less? Best analogy I can think of is a movie theatre charging $5 for a pint of spring water that costs them no more than a dime. Wouldn’t they sell at least five times more if they charged a dollar?

  2. July 20, 2021

    Ryan Radecki Reply

    I would imagine the price point for Quzyttir was thoughtfully selected from a team of analysts putting together a value-based price – potentially incorporating, perhaps, the revenue gain from reduced ED LOS if the drug were to offer some more rapid discharge, etc.

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603